CPI-1189

Overview

CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38 . CPI-1189 can inhibit apoptosis . CPI-1189 can be used in the study of HIV and neurological diseases.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-100376
• CAS No.: 183619-38-7
• Molecular Formula: C13H18N2O2
• Molecular Weight: 234.29
• Purity: 99.82%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution
• Availability: In-stock

Source

Original product source